The APBB2 Knockout Jurkat Polyclonal Cells are a genetically disrupted human T lymphocyte population generated through CRISPR/Cas9-mediated targeting of the APBB2 gene. This polyclonal knockout pool harbors site-specific disruptions, enabling loss-of-function studies without clonal selection biases. APBB2 encodes an adaptor protein that bridges amyloid precursor protein (APP) intracellular signaling with transcriptional regulation and apoptosis. By eliminating APBB2 expression across a diverse cell population, researchers can investigate its molecular functions while preserving the inherent variability of T cell biology.
The parental Jurkat cell line is a widely employed human T lymphocyte model derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. Jurkat cells are integral to studies of T cell receptor (TCR) signaling, immune activation, proliferation, and apoptosis. Their robust growth and well-characterized signaling networks make them a preferred platform for dissecting hematopoietic malignancy mechanisms and adaptive immunity. This polyclonal knockout pool retains Jurkat??s constitutive TCR activity while introducing APBB2 deficiency.
APBB2, also known as Fe65-like protein 1, functions as a critical adaptor that binds the APP intracellular domain (AICD) and assembles multimeric complexes with Fe65 (APBB1), Tip60, and other co-regulators. Within the APP processing pathway, APBB2 facilitates AICD-mediated transcriptional activation, influencing apoptosis and proliferation genes. The protein also interfaces with Notch and Wnt signaling, receiving input from Notch receptors and Wnt ligands, and converges on effectors such as p53 and Mdm2. By linking AICD to Tip60, APBB2 drives expression of genes controlling apoptosis and proliferation.
In Jurkat T cells, APBB2 knockout helps explore how APP/AICD signaling modulates TCR-mediated proliferation, cytokine responses, and apoptotic thresholds. This model provides insights into the convergence of neurodegenerative and immune pathways, with relevance to Alzheimer??s disease and acute lymphoblastic leukemia, where APP and adaptor protein dysregulation may play a role.
Researchers can use APBB2 Knockout Jurkat Polyclonal Cells in co-immunoprecipitation and western blotting to validate APBB2 loss and monitor AICD/Fe65 levels. Luciferase reporter assays quantify AICD-driven transcription, while flow cytometry with Annexin V detects apoptotic changes. RT-qPCR of targets such as p53 and Mdm2 reveals downstream transcriptional effects. These assays support drug discovery and signal transduction research in T lymphocytes. For further information, please contact Ascent Research.
